Abstract
This review gives an insight into the beginnings of dopamine transporter (DAT) imaging in the early 1990s, focussing on single photon emission tomography (SPECT). The development of the method and its consolidation as a now widely used clinical tool is described. The role of DAT-SPECT in the diagnosis and differential diagnosis of PD, atypical parkinsonian syndromes and several other different neurological disorders is reviewed. Finally the clinical research using DAT-SPECT as a biomarker for the progression of PD, for the detection of a preclinical dopaminergic lesion and its correlation with neuropathological findings is outlined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Does not apply.
References
Aquilonius SM, Bergström K, Eckernäs SA, Hartvig P, Leenders KL, Lundquist H, Antoni G, Gee A, Rimland A, Uhlin J (1987) In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 76(4):283–287. https://doi.org/10.1111/j.1600-0404.1987.tb03582.x
Asenbaum S, Brücke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wöber C, Müller C, Deecke L (1997) Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson’s disease. J Nucl Med 38(1):1–6
Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T (1998) [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm 105(10–12):1213–1228. https://doi.org/10.1007/s007020050124
Bani Sadr A, Testart N, Tylski P, Scheiber C (2019) Reduced scan time in 123I-FP-CIT SPECT imaging using a large-field cadmium-zinc-telluride camera. Clin Nucl Med 44(7):568–569. https://doi.org/10.1097/RLU.0000000000002554
Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000a) Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15(4):692–698. https://doi.org/10.1002/1531-8257(200007)15:4%3c692::aid-mds1014%3e3.0.co;2-v
Benamer H, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink M, Sips H, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Ries V (2000b) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123 I]-FP-CIT SPECT imaging: The [123 I]-FP-CIT study group. Mov Disord 15(3):503–510. https://doi.org/10.1002/1531-8257(200005)15:3%3c503::AID-MDS1013%3e3.0.CO;2-V
Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Höffken H, Gerstner A, Grosset DG (2003) Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 18(9):977–984. https://doi.org/10.1002/mds.10482
Boja JW, Patel A, Carroll FI, Rahman MA, Philip A, Lewin AH, Kopajtic TA, Kuhar MJ (1991) [125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194(1):133–134. https://doi.org/10.1016/0014-2999(91)90137-f
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(2):133–140. https://doi.org/10.1136/jnnp.62.2.133
Bordonne M, Chawki MB, Marie PY, Zaragori T, Roch V, Grignon R, Imbert L, Verger A (2020) High-quality brain perfusion SPECT images may be achieved with a high-speed recording using 360° CZT camera. EJNMMI Phys 7(1):65. https://doi.org/10.1186/s40658-020-00334-7
Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH (1999) Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53(5):1020–1025. https://doi.org/10.1212/wnl.53.5.1020
Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28(4):547–555. https://doi.org/10.1002/ana.410280412
Brown CA, Karimi MK, Tian L, Flores H, Su Y, Tabbal SD, Loftin SK, Moerlein SM, Perlmutter JS (2013) Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol 74(4):602–610. https://doi.org/10.1002/ana.23939
Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I (1993a) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm 94(2):137–146. https://doi.org/10.1007/BF01245007
Brücke T, Wenger S, Asenbaum S, Fertl E, Pfafflmeyer N, Müller C, Podreka I, Angelberger P (1993b) Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 60:494–500
Brücke T, Asenbaum S, Pozzera A, Hornykiewicz S, Harasko-van der Meer C, Wenger S, Koch G, Pirker W, Wöber C, Müller C (1994) Dopaminergic nerve cell loss in Parkinson’s disease quantified with 123I ß- CIT and SPECT correlates with clinical findings. Mov Disord 9(S1):120
Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, Wenger S, Ilieva D, van der HaraskoMeer C, Wessely P (1995) D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 15(3):513–518. https://doi.org/10.1038/jcbfm.1995.63
Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I (1997) Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9–24
Brücke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I (2000) SPECT and PET imaging of the dopaminergic system in Parkinson’s disease. J Neurol. https://doi.org/10.1007/pl00007769
Colloby SJ, McParland S, O’Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain J Neurol 135(Pt 9):2798–2808. https://doi.org/10.1093/brain/aws211
Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G (1997) Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 24(3):320–325. https://doi.org/10.1007/BF01728771
Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K (1998) Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. J Nucl Med 39(7):1138–1142
Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K (2000) Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain J Neurol 123(Pt 6):1155–1160. https://doi.org/10.1093/brain/123.6.1155
Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP (2016) What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. J Neurol Neurosurg Psychiatry 87(3):319–323. https://doi.org/10.1136/jnnp-2014-310256
Fahn S, Williams DT (1988) Psychogenic dystonia. Adv Neurol 50:431–455
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Eng J Med 351(24):2498–2508. https://doi.org/10.1056/NEJMoa033447
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain J Neurol 114(Pt 5):2283–2301. https://doi.org/10.1093/brain/114.5.2283
Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol 34(3):423–431. https://doi.org/10.1002/ana.410340331
Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305(5930):137–138. https://doi.org/10.1038/305137a0
Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, Zijlmans JC, Hoffmann M, Brücke T (2002) [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord 17(3):518–523. https://doi.org/10.1002/mds.10092
Honkanen EA, Saari L, Orte K, Gardberg M, Noponen T, Joutsa J, Kaasinen V (2019) No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson’s disease. Mov Dis 34(10):1562–1566. https://doi.org/10.1002/mds.27777
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42(6):1142–1146. https://doi.org/10.1212/wnl.42.6.1142
Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57(8):1497–1499. https://doi.org/10.1212/wnl.57.8.1497
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain J Neurol 125(Pt 4):861–870. https://doi.org/10.1093/brain/awf080
Innis RB (1994) Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson’s disease. Eur J Nucl Med 21(1):1–5. https://doi.org/10.1007/BF00182298
Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90(24):11965–11969. https://doi.org/10.1073/pnas.90.24.11965
Iranzo A, Santamaría J, Valldeoriola F, Serradell M, Salamero M, Gaig C, Niñerola-Baizán A, Sánchez-Valle R, Lladó A, De Marzi R, Stefani A, Seppi K, Pavia J, Högl B, Poewe W, Tolosa E, Lomeña F (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82(3):419–428. https://doi.org/10.1002/ana.25026
Janowsky A, Vocci F, Berger P, Angel I, Zelnik N, Kleinman JE, Skolnick P, Paul SM (1987) [3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson’s disease. J Neurochem 49(2):617–621. https://doi.org/10.1111/j.1471-4159.1987.tb02908.x
Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB (1998a) Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43(6):792–800. https://doi.org/10.1002/ana.410430614
Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC (1998b) Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psychiatry 65(1):60–64. https://doi.org/10.1136/jnnp.65.1.60
Kaasinen V, Vahlberg T (2017) Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 82(6):873–882. https://doi.org/10.1002/ana.25103
Karimi M, Tian L, Brown CA, Flores HP, Loftin SK, Videen TO, Moerlein SM, Perlmutter JS (2013) Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 73(3):390–396. https://doi.org/10.1002/ana.23798
Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s-diseased striatum. Synapse 9(1):43–49. https://doi.org/10.1002/syn.890090107
Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W (2014) Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29(14):1767–1773. https://doi.org/10.1002/mds.25975
Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S (1996) Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res 68(1):23–30. https://doi.org/10.1016/s0925-4927(96)02839-9
Küfferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brücke T, Kasper S (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 133(4):323–328. https://doi.org/10.1007/s002130050409
Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS (1986) Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20(2):258–262. https://doi.org/10.1002/ana.410200212
Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989) Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol 36(4):518–524
Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46(1):231–237. https://doi.org/10.1212/wnl.46.1.231
Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 57(11):2089–2094. https://doi.org/10.1212/wnl.57.11.2089
Marek K, Jennings D, Seibyl J (2003) Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology 61(6 Suppl 3):S43–S48. https://doi.org/10.1212/wnl.61.6_suppl_3.s43
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Initiative PPM (2018) The Parkinson’s progression markers initiative (PPMI)—establishing a PD biomarker cohort. Ann Clin Transl Neurol 5(12):1460–1477. https://doi.org/10.1002/acn3.644
Marshall V, Grosset DG (2003) Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 18(Suppl 7):S22–S27. https://doi.org/10.1002/mds.10574
Marttila RJ, Rinne UK (1976) Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand 53(2):81–102. https://doi.org/10.1111/j.1600-0404.1976.tb04328.x
Meara J, Bhowmick BK, Hobson P (1999) Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 28(2):99–102. https://doi.org/10.1093/ageing/28.2.99
Miyasaki JM, Sa DS, Galvez-Jimenez N, Lang AE (2003) Psychogenic movement disorders. Can J Neurol Sci 30(Suppl 1):S94–S100. https://doi.org/10.1017/s0317167100003292
Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, Brooks DJ, Darcourt J, Dickson JC, Douglas D, Drzezga A, Dubroff J, Ekmekcioglu O, Garibotto V, Herscovitch P, Kuo P, Lammertsma A, Pappata S, Peñuelas I, Seibyl J, Law I (2020) EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nuclear Med Mol Imaging 47(8):1885–1912. https://doi.org/10.1007/s00259-020-04817-8
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64(3):314–319. https://doi.org/10.1136/jnnp.64.3.314
Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brücke T (1997) [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 12(3):448–451. https://doi.org/10.1002/mds.870120330
Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, Sybirska E, Al-Tikriti M, Charney DS, Malison RT (1991) [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34(10):3144–3146. https://doi.org/10.1021/jm00114a027
Nishida Y, Yokota T (2021) Reversible reduction of dopamine transporter uptake in a case of hydrocephalus. Ann Neurol 90(2):326–327. https://doi.org/10.1002/ana.26130
Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO (2000) Progression in Parkinson’s disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47(6):804–808
Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931–1938. https://doi.org/10.1001/jama.284.15.1931
Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653–1661. https://doi.org/10.1001/jama.287.13.1653
Parkinson Study Group PRECEPT Investigators (2007) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69(15):1480–1490. https://doi.org/10.1212/01.wnl.0000277648.63931.c0
Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W (2012) Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov Disord 27(1):65–71. https://doi.org/10.1002/mds.24000
Perlmutter JS, Stoessl AJ (2019) Striatal DAT SPECT: caveat emptor! Mov Disord 34(10):1430–1432. https://doi.org/10.1002/mds.27811
Piccini PP (2003) Dopamine transporter: basic aspects and neuroimaging. Mov Disord 18(Suppl 7):S3–S8. https://doi.org/10.1002/mds.10571
Pifl C (2019) The time delay between in vivo imaging and postmortem data poses a caveat on “no link” findings. Mov Disord 34(10):1579–1580. https://doi.org/10.1002/mds.27847
Pimoule C, Schoemaker H, Javoy-Agid F, Scatton B, Agid Y, Langer SZ (1983) Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson’s disease. Eur J Pharmacol 95(1–2):145–146. https://doi.org/10.1016/0014-2999(83)90281-9
Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):S43–S51. https://doi.org/10.1002/mds.10579
Pirker W (2015) Update: SPECT in der Diagnostik von Parkinson-Syndromen. J Neurol Neurochir Psychiatry 16(2):60–71
Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brücke T (1995) beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100(3):247–256. https://doi.org/10.1007/BF01276462
Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, Brücke T (2000) [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15(6):1158–1167. https://doi.org/10.1002/1531-8257(200011)15:6%3c1158::aid-mds1015%3e3.0.co;2-0
Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brücke T (2002) Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17(1):45–53. https://doi.org/10.1002/mds.1265
Poewe W, Scherfler C (2003) Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 18(Suppl 7):S16–S21. https://doi.org/10.1002/mds.10573
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56(2):173–181. https://doi.org/10.1002/ana.20160
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
Rajput AH, Jamieson H, Hirsh S, Quraishi A (1975) Relative efficacy of alcohol and propranolol in action tremor. Can J Neuroll Sci 2(1):31–35. https://doi.org/10.1017/s0317167100019958
Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK (2001) Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 28(10):1523–1528. https://doi.org/10.1007/s002590100571
Rinne JO, Kuikka JT, Bergström KA, Rinne UK (1995) Striatal dopamine transporter in different disability stages of Parkinson’s disease studied with [(123)I]beta-CIT SPECT. Parkinsonism Relat Disord 1(1):47–51. https://doi.org/10.1016/1353-8020(95)00012-u
Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V (2017) Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88(15):1461–1467. https://doi.org/10.1212/WNL.0000000000003810
Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry 73(5):529–534. https://doi.org/10.1136/jnnp.73.5.529
Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38(4):589–598. https://doi.org/10.1002/ana.410380407
Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Parkinson’s Progression Marker Initiative* (2018) Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Mov Disord 33(5):771–782. https://doi.org/10.1002/mds.27361
Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, PPMI Investigators (2020) Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s progression markers initiative (PPMI): a cross-sectional study. Lancet Neurol 19(1):71–80. https://doi.org/10.1016/S1474-4422(19)30319-9
Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34(3):324–330. https://doi.org/10.1002/ana.410340304
Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G (2000) Measuring the progression of idiopathic Parkinson’s disease with [123I] beta-CIT SPECT. J Neural Transm 107(5):543–552. https://doi.org/10.1007/s007020070077
Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C (2002) Islington study of dementia subtypes in the community. Br J Psychiatry 180:270–276. https://doi.org/10.1192/bjp.180.3.270
Swanberg MM, Cummings JL (2002) Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf 25(7):511–523. https://doi.org/10.2165/00002018-200225070-00005
Tatsch K, Schwarz J, Oertel WH, Kirsch CM (1991) SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 12(8):699–707. https://doi.org/10.1097/00006231-199108000-00005
Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S (1999) In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141(2):175–181. https://doi.org/10.1007/s002130050822
Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28–S33. https://doi.org/10.1002/mds.10575
van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB (1995) Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nuclear Med 36(7):1175–1181
Varrone A, Pellecchia MT (2018) SPECT molecular imaging in familial Parkinson’s disease. Int Rev Neurobiol 142:225–260. https://doi.org/10.1016/bs.irn.2018.09.004
Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16(6):1023–1032. https://doi.org/10.1002/mds.1256
Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E (2021) Single photon emission computed tomography/positron emission tomography molecular imaging for parkinsonism: a fast-developing field. Ann Neurol 90(5):711–719. https://doi.org/10.1002/ana.26187
Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, Hitzemann R, Wolf AP (1994) Decreased dopamine transporters with age in health human subjects. Ann Neurol 36(2):237–239. https://doi.org/10.1002/ana.410360218
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73(2):134–140. https://doi.org/10.1136/jnnp.73.2.134
Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78(11):1176–1181. https://doi.org/10.1136/jnnp.2006.110122
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54(1):93–101. https://doi.org/10.1002/ana.10609
Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56(1):98–102. https://doi.org/10.1001/archneur.56.1.98
Acknowledgements
The authors would like to thank Mrs. Nicki Schiller for language editing and Verena Reindl and Dr. Juan Flores from the Isotopix institute in Vienna for their courtesy to use SPECT images for Fig 3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Brücke, T., Brücke, C. Dopamine transporter (DAT) imaging in Parkinson’s disease and related disorders. J Neural Transm 129, 581–594 (2022). https://doi.org/10.1007/s00702-021-02452-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-021-02452-7